Iterative Design Reveals Molecular Domain Relationships in Supramolecular Peptide-Drug Conjugates

被引:2
|
作者
Sis, Matthew J. [1 ]
Liu, Dongping [1 ]
Allen, Isabella [1 ]
Webber, Matthew J. [1 ]
机构
[1] Univ Notre Dame, Dept Chem & Biomol Engn, Notre Dame, IN 46556 USA
基金
美国国家科学基金会;
关键词
POTENTIAL PRODRUGS; AMPHIPHILES; NANOFIBERS; DELIVERY; ESTERS;
D O I
10.1021/acs.biomac.4c00519
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Supramolecular peptide-drug conjugates (sPDCs) are prepared by covalent attachment of a drug moiety to a peptide motif programmed for one-dimensional self-assembly, with subsequent physical entanglement of these fibrillar structures enabling formation of nanofibrous hydrogels. This class of prodrug materials presents an attractive platform for mass-efficient and site-specific delivery of therapeutic agents using a discrete, single-component molecular design. However, a continued challenge in sPDC development is elucidating relationships between supramolecular interactions in their drug and peptide domains and the resultant impacts of these domains on assembly outcomes and material properties. Inclusion of a saturated alkyl segment alongside the prodrug in the hydrophobic domain of sPDCs could relieve some of the necessity for ordered, prodrug-produg interactions. Accordingly, nine sPDCs are prepared here to iterate the design variables of amino acid sequence and hydrophobic prodrug-alkyl block design. All molecules spontaneously formed hydrogels under physiological conditions, indicating a less hindered thermodynamic path to self-assembly relative to previous prodrug-only designs. However, material studies on the supramolecular arrangement, formation, and mechanical properties of the resultant sPDC hydrogels as well as their drug release profiles showed complex relationships between the hydrophobic and peptide domains in the formation and function of the resulting assemblies. Together, these results indicate that sPDC material properties are intrinsically linked to holistic molecular design with coupled contributions from their prodrug and peptide domains in directing properties of the emergent materials.
引用
收藏
页码:4482 / 4491
页数:10
相关论文
共 50 条
  • [31] Source and exploration of the peptides used to construct peptide-drug conjugates
    Zhou, Jiaqi
    Li, Yuanyuan
    Huang, Wenlong
    Shi, Wei
    Qian, Hai
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 224
  • [32] Targeting of peptide-binding receptors on cancer cells with peptide-drug conjugates
    Worm, Dennis J.
    Els-Heindl, Sylvia
    Beck-Sickinger, Annette G.
    PEPTIDE SCIENCE, 2020, 112 (03)
  • [33] Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
    Mo Wu
    Wei Huang
    Nan Yang
    Yanyong Liu
    Experimental Hematology & Oncology, 11
  • [34] Peptide-Drug Conjugate: A Novel Drug Design Approach
    Ma, Liang
    Wang, Chao
    He, Zihao
    Cheng, Biao
    Zheng, Ling
    Huang, Kun
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (31) : 3373 - 3396
  • [35] Autocatalytic strategy for tuning drug release from peptide-drug supramolecular hydrogel
    Yuqin Wu
    Tian Xia
    Xiaohui Ma
    Lei Lei
    Lulu Du
    Xiaoning Xu
    Xiangyi Liu
    Yueting Shi
    Xingyi Li
    Deqing Lin
    ChineseChemicalLetters, 2023, 34 (10) : 220 - 224
  • [36] Controlled release of free doxorubicin from peptide-drug conjugates by drug loading
    Chen, Zhipeng
    Zhang, Pengcheng
    Cheetham, Andrew G.
    Moon, Jae Hyon
    Moxley, James W., Jr.
    Lin, Yi-an
    Cui, Honggang
    JOURNAL OF CONTROLLED RELEASE, 2014, 191 : 123 - 130
  • [37] Autocatalytic strategy for tuning drug release from peptide-drug supramolecular hydrogel
    Wu, Yuqin
    Xia, Tian
    Ma, Xiaohui
    Lei, Lei
    Du, Lulu
    Xu, Xiaoning
    Liu, Xiangyi
    Shi, Yueting
    Li, Xingyi
    Lin, Deqing
    CHINESE CHEMICAL LETTERS, 2023, 34 (10)
  • [38] Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy
    Lindberg, Jakob
    Nilvebrant, Johan
    Nygren, Per-Ake
    Lehmann, Fredrik
    MOLECULES, 2021, 26 (19):
  • [39] Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs)
    Cooper, Bethany M.
    Iegre, Jessica
    O' Donovan, Daniel H.
    Halvarsson, Maria Olwegard
    Spring, David R.
    CHEMICAL SOCIETY REVIEWS, 2021, 50 (03) : 1480 - 1494
  • [40] Recent progress in the development of peptide-drug conjugates (PDCs) for cancer therapy
    He, Haiqi
    Deng, Xin
    Wang, Zhijie
    Chen, Jianjun
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 284